The FDA released draft guidance that would, in some cases, lower the data requirements for biosimilar development by allowing use of comparator product data from outside the U.S. The agency said the change aims to reduce development costs and speed market entry for biosimilars, a move that could expand competition and lower prices for biologic medicines. Regulators emphasized robust analytical comparability remains central, but relaxed clinical bridging in defined scenarios could cut timelines and capital needs for copycat developers. The shift follows European precedents where biosimilar uptake is higher. Industry stakeholders expect the guidance to spur new biosimilar programs, particularly for oncology and autoimmune biologics, but warned patent and supply chain hurdles will still shape the pace of real‑world competition.